Dianthus Therapeutics Operating Cycle Over Time
| DNTH Stock | 53.36 2.86 5.66% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dianthus Therapeutics Performance and Dianthus Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Cycle Analysis
Compare Dianthus Therapeutics and related stocks such as Enliven Therapeutics, Taysha Gene Therapies, and Sana Biotechnology Operating Cycle Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| TSHA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| SANA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ATAI | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 113 | 8.8 K | 2.6 K | 1.6 K | 1.8 K | 3.6 K |
| NKTR | 15.4974 | 236 | 245 | 133 | 172 | 153 | 169 | 134 | 183 | 333 | 379 | 312 | 357 | 169 | 5.9667 | 5.37 | 5.1 |
| ANAB | 33.5317 | 33.5317 | 33.5317 | 33.5317 | 33.5317 | 25.4675 | 117 | 58.4365 | 12.702 | 5.0612 | 5.0612 | 5.0612 | 50.3485 | 146 | 163 | 147 | 154 |
| OCS | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 413 | 372 | 331 |
| BBOT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| IMTX | 176 | 176 | 176 | 176 | 176 | 176 | 176 | 176 | 176 | 65.1255 | 52.1085 | 24.7687 | 2.3463 | 38.78 | 15.7983 | 18.17 | 17.26 |
Dianthus Therapeutics and related stocks such as Enliven Therapeutics, Taysha Gene Therapies, and Sana Biotechnology Operating Cycle description
My Equities
My Current Equities and Potential Positions
| Dianthus Therapeutics | DNTH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7 Times Square, |
| Exchange | NASDAQ Exchange |
null 53.36
Check out Dianthus Therapeutics Performance and Dianthus Therapeutics Correlation. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Dianthus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.